Home Cart Sign in  
Chemical Structure| 39012-20-9 Chemical Structure| 39012-20-9

Structure of Picroside II
CAS No.: 39012-20-9

Chemical Structure| 39012-20-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Picroside II is a natural product isolated and purified from the roots of Picrorhiza scrophulariiflora, with anti-apoptotic and anti-inflammatory activities.

Synonyms: Ampicoside; 6-Vanilloylcatalpol; Vanilloyl catalpol

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Picroside II

CAS No. :39012-20-9
Formula : C23H28O13
M.W : 512.46
SMILES Code : O[C@H]([C@H]([C@@H]([C@@H](CO)O1)O)O)[C@@H]1O[C@H]2[C@@]3([H])[C@@]([C@H](OC(C4=CC=C(O)C(OC)=C4)=O)[C@@]5([H])[C@]3(CO)O5)([H])C=CO2
Synonyms :
Ampicoside; 6-Vanilloylcatalpol; Vanilloyl catalpol
MDL No. :MFCD00135962

Safety of Picroside II

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HepG2 cells 10 µM 2 hours pretreatment followed by 20 hours FFAs treatment Picroside II pretreatment inhibited FFAs-induced lipid accumulation by attenuating the expression of FATP5, SREBP-1, and SCD, thereby reducing fatty acid uptake and lipogenesis. Additionally, Picroside II decreased the expression of FOXO1 and PEPCK, leading to reduced gluconeogenesis. Clin Mol Hepatol. 2018 Mar;24(1):77-87
HUVECs 50 μg/mL, 100 μg/mL, 200 μg/mL 24 hours Picroside II significantly reduced HHcy-induced NADPH oxidase activation and ROS formation, restored SOD and CAT activity in a concentration-dependent manner, inhibited NF-κB activation and proinflammatory cytokines expression, and decreased cell apoptosis. J Cell Mol Med. 2019 Jan;23(1):464-475
Pancreatic cancer cell lines (PANC-1, SW1990) 300 µM 3 hours To evaluate the effect of Picroside II on the proliferation and invasion ability of pancreatic cancer cells. Results showed that Picroside II treatment significantly inhibited the proliferation and invasion ability of PDAC cells. Redox Biol. 2025 Jul;84:103665
THP-1 human monocytes Up to 20 µM 6 hours Picroside II dose-dependently inhibited LPS-induced SAA1 mRNA expression, while dexamethasone (DEX) enhanced it. Molecules. 2019 May 27;24(10):2020

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c nude mice Subcutaneous xenograft model Intraperitoneal injection 0.4 mg/kg Three times a week for one month To evaluate the inhibitory effect of Picroside II on PDAC tumor growth. Results showed that Picroside II significantly inhibited PDAC tumor growth. Redox Biol. 2025 Jul;84:103665
Wistar rats Myocardial ischemia reperfusion injury model Perfusion 1 µM, 10 µM, 100 µM Single administration, lasting 20 minutes Picroside II significantly improved postischemic myocardial function, reduced myocardial infarct size, inhibited apoptosis, increased myocardial NO content, upregulated Bcl-2, downregulated Bax, and increased the phosphorylation of Akt and endothelial NOS. Drug Des Devel Ther. 2014 May 14;8:545-54
Wistar rats Middle cerebral artery occlusion/reperfusion model Intravenous injection into the tail vein 10 mg/kg Administered after 2 hours of ischemia, followed by 22 hours of reperfusion Picroside II inhibits neuronal apoptosis and improves neurological function in rats after cerebral ischemia-reperfusion injury Int J Mol Sci. 2010 Nov 16;11(11):4580-90
Wistar Albino rats Hind limb ischemia-reperfusion injury model Intraperitoneal injection 10 mg/kg Single dose, 30 minutes before ischemia To investigate the protective effect of Picroside II on hind limb ischemia-reperfusion injury in rats. Results showed that Picroside II significantly reduced oxidative stress (TOS) and apoptosis, and improved antioxidant status (TAS). Drug Des Devel Ther. 2017 Jun 26;11:1917-1925
Wistar Albino rats Hind limb ischemia reperfusion injury model Intraperitoneal injection 10 mg/kg Single dose 30 minutes before ischemia To evaluate the effect of picroside II on lipid peroxidation and erythrocyte deformability during hind limb I/R injury. Results showed that picroside II pretreatment significantly prevented the I/R-induced increase in erythrocyte deformability index, MDA levels, and NO activity. Drug Des Devel Ther. 2016 Mar 1;10:927-31
C57BL mice Hyperhomocysteinemia model Oral 10 mg/kg, 60 mg/kg Once daily for 8 weeks Picroside II significantly decreased aortic endothelial NADPH oxidase activity and plasma MDA levels, increased SOD activity, reduced inflammatory cytokines expression, and protected endothelial function by regulating the SIRT1/LOX-1 signaling pathway. J Cell Mol Med. 2019 Jan;23(1):464-475
Wistar rats Middle cerebral artery occlusion (MCAO) model Intraperitoneal injection 5 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg 1.0 h, 1.5 h, 2.0 h, 2.5 h after ischemia To explore the optimal therapeutic dose and time window of picroside II for treating cerebral ischemic injury in rats, the results showed that the best combination was ischemia 1.5 h with 20 mg/kg body weight Int J Mol Sci. 2012;13(3):2551-2562

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.95mL

0.39mL

0.20mL

9.76mL

1.95mL

0.98mL

19.51mL

3.90mL

1.95mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories